12:44 PM EST, 02/18/2025 (MT Newswires) -- GSK (GSK) said in a Tuesday filing that the US Food and Drug Administration approved its meningococcal vaccine Penmenvy for people aged 10 to 25 years.

The vaccine targets five common Neisseria meningitidis serogroups to simplify protection against meningococcal disease. Penmenvy combines components from GSK's existing meningococcal vaccines, Bexsero and Menveo, the company said.

The US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is set to discuss recommendations for Penmenvy on Feb. 26, the company added.

Shares of GSK were up 1.1% in recent trading.

Price: 36.58, Change: +0.41, Percent Change: +1.12